ERBITUX Solution for infusion (2019)
Active ingredients: Cetuximab
Product Name and Form
Erbitux 5 mg/mL solution for infusion.
Solution for infusion.
Qualitative and Quantitative Composition
Each mL of solution for infusion contains 5 mg cetuximab.
Each vial of 20 mL contains 100 mg cetuximab. Each vial of 100 mL contains 500 mg cetuximab.
Cetuximab is a chimeric monoclonal IgG1 antibody produced in a mammalian cell line (Sp2/0) by recombinant DNA technology.
For the full list of excipients, see section 6.1.
Cetuximab is a chimeric monoclonal IgG1 antibody that is specifically directed against the epidermal growth factor receptor (EGFR). EGFR signalling pathways are involved in the control of cell survival, cell cycle progression, angiogenesis, cell migration and cellular invasion/metastasis. Cetuximab blocks binding of endogenous EGFR ligands resulting in inhibition of the function of the receptor.
Citric acid monohydrate
Water for injections
Pack sizes and Marketing
20 mL or 100 mL of solution in a vial (Type I glass) with a stopper (halobutyl rubber) and a seal (aluminium/polypropylen).
Pack size of 1 vial.
Not all vial sizes may be marketed.
Merck KGaA, 64271, Darmstadt, Germany
Date of first authorisation: 29/06/2004
Date of latest renewal: 29/06/2009